Related Experiment Video

Updated: May 3, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.7K

[The first Italian patient affected by diffuse large B-cell lymphoma treated with axi-cel in the second line:

Stefania Bramanti1, Davide Chizzoniti1, Daniele Mannina1

  • 1Terapia Cellulare e CAR -T, Humanitas Cancer Center, Rozzano (Milano).

Recenti Progressi in Medicina
|February 11, 2025
PubMed

CAR-T cell therapy has revolutionized the treatment of refractory or relapsed diffuse large B-cell lymphoma (DLBCL) within 12 months, replacing the use of high-dose chemotherapy with autologous stem cell reinfusion. Primary chemoresistance remains one of the most unfavorable prognostic scenarios for patients with DLBCL, despite the progress made with the introduction of anti-CD20 monoclonal antibodies in first-line treatment. Early identification of prognostic factors associated with clinical presentation represents an integrated approach that ensures rapid access to autologous anti-CD19 CAR-T therapy in selected cases that may benefit from treatment according to current standard indications.

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

2.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K